120 related articles for article (PubMed ID: 37318494)
1. The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer.
Essa NM; Elgendy MO; Gabr A; Mahmoud MM; Alharbi AA; Tashkandi HM; Salem HF; Harakeh S; Boshra MS
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5200-5210. PubMed ID: 37318494
[TBL] [Abstract][Full Text] [Related]
2. Metformin may protect nondiabetic breast cancer women from metastasis.
El-Haggar SM; El-Shitany NA; Mostafa MF; El-Bassiouny NA
Clin Exp Metastasis; 2016 Apr; 33(4):339-57. PubMed ID: 26902691
[TBL] [Abstract][Full Text] [Related]
3. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy.
Pimentel I; Lohmann AE; Ennis M; Dowling RJO; Cescon D; Elser C; Potvin KR; Haq R; Hamm C; Chang MC; Stambolic V; Goodwin PJ
Breast; 2019 Dec; 48():17-23. PubMed ID: 31472446
[TBL] [Abstract][Full Text] [Related]
4. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.
Varewijck AJ; Janssen JA; Vähätalo M; Hofland LJ; Lamberts SW; Yki-Järvinen H
Diabetologia; 2012 Apr; 55(4):1186-94. PubMed ID: 22237688
[TBL] [Abstract][Full Text] [Related]
5. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.
Goodwin PJ; Parulekar WR; Gelmon KA; Shepherd LE; Ligibel JA; Hershman DL; Rastogi P; Mayer IA; Hobday TJ; Lemieux J; Thompson AM; Pritchard KI; Whelan TJ; Mukherjee SD; Chalchal HI; Oja CD; Tonkin KS; Bernstein V; Chen BE; Stambolic V
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25740979
[TBL] [Abstract][Full Text] [Related]
6. Metformin and survival in diabetic patients with breast cancer.
El-Benhawy SA; El-Sheredy HG
J Egypt Public Health Assoc; 2014 Dec; 89(3):148-53. PubMed ID: 25534180
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
DeCensi A; Puntoni M; Gandini S; Guerrieri-Gonzaga A; Johansson HA; Cazzaniga M; Pruneri G; Serrano D; Schwab M; Hofmann U; Mora S; Aristarco V; Macis D; Bassi F; Luini A; Lazzeroni M; Bonanni B; Pollak MN
Breast Cancer Res Treat; 2014 Nov; 148(1):81-90. PubMed ID: 25253174
[TBL] [Abstract][Full Text] [Related]
8. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.
Karnevi E; Said K; Andersson R; Rosendahl AH
BMC Cancer; 2013 May; 13():235. PubMed ID: 23663483
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.
Quinn BJ; Dallos M; Kitagawa H; Kunnumakkara AB; Memmott RM; Hollander MC; Gills JJ; Dennis PA
Cancer Prev Res (Phila); 2013 Aug; 6(8):801-10. PubMed ID: 23771523
[TBL] [Abstract][Full Text] [Related]
10. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
[TBL] [Abstract][Full Text] [Related]
11. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
[TBL] [Abstract][Full Text] [Related]
12. Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial.
Zheng Y; Zhu J; Zhang H; Liu Y; Sun H
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1349-1357. PubMed ID: 31628524
[TBL] [Abstract][Full Text] [Related]
13. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
Campagnoli C; Pasanisi P; Abbà C; Ambroggio S; Biglia N; Brucato T; Colombero R; Danese S; Donadio M; Venturelli E; Zito G; Berrino F
Clin Breast Cancer; 2012 Jun; 12(3):175-82. PubMed ID: 22607767
[TBL] [Abstract][Full Text] [Related]
14. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
15. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
[TBL] [Abstract][Full Text] [Related]
16. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
Rozengurt E; Sinnett-Smith J; Kisfalvi K
Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
[TBL] [Abstract][Full Text] [Related]
18. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
19. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
20. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
Herrmann BL; Berg C; Vogel E; Nowak T; Renzing-Koehler K; Mann K; Saller B
Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
